Search

Introduccion y objetivos Los estudios previos en los que se ha abordado la influencia de la enfermedad de Chagas en la mortalidad de pacientes con insuficiencia cardiaca han tenido la limitacion de la heterogeneidad de la poblacion estudiada. Existen pocos datos sobre la asociacion entre la causa subyacente de la miocardiopatia dilatada y el pronostico a largo plazo. El objetivo de este estudio es identificar los factores de riesgo de mortalidad en pacientes con miocardiopatia dilatada secundaria a enfermedad de Chagas o idiopatica, y determinar el valor pronostico de la identificacion de la enfermedad de Chagas como etiologia subyacente de la miocardiopatia dilatada. Metodos Hemos evaluado la evolucion de 287 pacientes con insuficiencia cardiaca secundaria a miocardiopatia dilatada. Se agrupo a los pacientes en dos categorias segun la causa subyacente: miocardiopatia de Chagas (224 pacientes) y miocardiopatia dilatada idiopatica (63 pacientes). Las variables de valoracion fueron la muerte y el trasplante cardiaco. Resultados A lo largo de una mediana de seguimiento de 39,5 meses, fallecieron 104 pacientes y se practico un trasplante cardiaco a 9. En un analisis de riesgos proporcionales de Cox multivariable, la clase funcional de la NYHA, la fraccion de eyeccion ventricular izquierda, la funcion ventricular derecha y el volumen auricular izquierdo se mantuvieron como factores predictivos de una evolucion adversa. La etiologia de Chagas se asocio de manera independiente a un mal pronostico (razon de riesgos = 2,48; intervalo de confianza del 95%, 1,28-4,78; p = 0,007) en comparacion con la idiopatica, tras introducir un ajuste respecto a otros parametros predictivos bien establecidos en la insuficiencia cardiaca. Conclusiones La identificacion de la etiologia de Chagas en pacientes con miocardiopatia dilatada tiene importancia pronostica. La miocardiopatia de Chagas se asocio a una supervivencia peor que la de la idiopatica, con independencia de los demas factores clinicos y ecocardiograficos de mal pronostico en la insuficiencia cardiaca.

FUNDAMENTO: A reserva contrátil diminuída pode já estar presente em pacientes portadores de regurgitação aórtica, assintomáticos com fração de ejeção (FE) normal, indicando a necessidade de avaliações frequentes e acuradas da função ventricular esquerda para detectar disfunção sistólica incipiente. OBJETIVO: Analisar se incrementos na FE em doses baixas de dobutamina podem predizer cirugia e/ou morte em pacientes com regurgitação aórtica. MÉTODOS: Eco de estresse com dobutamina foi realizado em 24 pacientes portadores de regurgitação aórtica para verificar se incrementos da FE em doses baixas de dobutamina seriam capazes de predizer a necessidade de cirurgia e/ou morte nesse grupo de pacientes. RESULTADOS: A idade média foi de 37,8±16,8 anos, e 16 (66%) eram homens. A FE aumentou de um valor basal médio de 62,3±7,9% para 71,5±10,5%, na dose de 20 µg/kg/min de dobutamina (p < 0,001). Os pacientes foram acompanhados por 36,6±20,1 meses: dois pacientes morreram (um de morte cardiovascular) e cinco foram submetidos à cirurgia cardíaca. A FE basal se correlacionou com cirurgia e morte no seguimento de pacientes. CONCLUSÃO: A FE basal se correlacionou com cirurgia ou morte no seguimento de pacientes jovens com regurgitação aórtica. Porém, o incremento percentual na FE com dose baixa de dobutamina não foi capaz de predizer eventos nesses pacientes. BACKGROUND: Decreased contractile reserve may already be present in asymptomatic patients with aortic regurgitation and normal ejection fraction (EF), thus indicating the need for frequent and accurate assessments of the left ventricular function for the early detection of systolic dysfunction. OBJECTIVE: To analyze if increments in EF with low dose dobutamine could predict surgery and/or death in patients with aortic regurgitation. METHDOS: Dobutamine-stress echocardiography was performed in 24 patients with aortic regurgitation in order to analyze whether EF increments at low dobutamine doses could predict the need for surgery and/or death in this group of patients. RESULTS: Mean age was 37.8±16.8 years and 16 patients (66%) were male. EF increased from a mean baseline value of 62.3±7.9% to 71.5±10.5% at a dobutamine dose of 20 µg/kg/min (p

Decreased contractile reserve may already be present in asymptomatic patients with aortic regurgitation and normal ejection fraction (EF), thus indicating the need for frequent and accurate assessments of the left ventricular function for the early detection of systolic dysfunction.To analyze if increments in EF with low dose dobutamine could predict surgery and/or death in patients with aortic regurgitation.Dobutamine-stress echocardiography was performed in 24 patients with aortic regurgitation in order to analyze whether EF increments at low dobutamine doses could predict the need for surgery and/or death in this group of patients.Mean age was 37.8+/-16.8 years and 16 patients (66%) were male. EF increased from a mean baseline value of 62.3+/-7.9% to 71.5+/-10.5% at a dobutamine dose of 20 microg/kg/min (p0.001). The patients were followed-up for 36.6+/-20.1 months; two patients died (one of cardiovascular death) and five underwent cardiac surgery. Baseline EF was correlated with surgery and death in the follow-up of patients.Baseline EF was correlated with surgery or death in the follow-up of young patients with aortic regurgitation. However, the percentage increase in EF at low dobutamine doses did not allow us to predict events in these patients.

OBJECTIVE: To investigate whether patients with heart valve prostheses and similar International Normalized Ratios (INR) have the same level of protection against thromboembolic events, that is, whether the anticoagulation intensity is related to the intensity of hypercoagulability supression. METHODS: INR and plasma levels of prothrombin fragment 1+2 (F1+2) were assessed in blood samples of 27 patients (7 with mechanical heart valves and 20 with biological heart valves) and 27 blood samples from healthy donors that were not taking any medication. RESULTS: Increased levels of F1+2 were observed in blood samples of 5 patients with heart valve prostheses taking warfarin. These findings reinforce the idea that even though patients may have INRs, within the therapeutic spectrum, they are not free from new thromboembolic events. CONCLUSION: Determination of the hypercoagulability marker F1+2 might result in greater efficacy and safety for the use of oral anticoagulants, resulting in improved quality of life for patients.

OBJETIVO: Descrever os achados ao ecocardiograma transesofágico e evolução clínica de portadores de flail mitral valve. MÉTODOS: No período de janeiro/93 a março/97, 1675 pacientes foram submetidos, em nossa instituição, a ecocardiograma transesofágico, sendo que em 35 casos foi feito o diagnóstico de flail mitral valve e, posteriormente, obtida sua evolução clínica. RESULTADOS: A idade dos pacientes variou 12 a 87 anos (média 65±15) e 27 (77%) eram do sexo masculino. O folheto posterior foi o mais acometido (25 pacientes, 71%). O mecanismo do flail foi ruptura de cordoalha tendínea em todos os casos, exceto um, que apresentava importante alongamento e redundância de cordoalha. A etiologia foi prolapso e/ou degeneração mixomatosa em 15 pacientes, degenerativa em 9, isquêmica em 5, reumática em 4 e endocardite em 3. Regurgitação mitral de grau importante ocorreu em 25 (71%) pacientes e moderada em 10 (29%). O tempo médio de acompanhamento foi de 375±395 dias (1 a 1380). Foram submetidos a tratamento clínico 19 pacientes e a tratamento cirúrgico 16, sendo que em todos foi confirmado o diagnóstico transesofágico. O número total de óbitos (hospitalar e pós-hospitalar) foi alto (34%), tanto em pacientes submetidos a tratamento clínico quanto cirúrgico. Entre os sobreviventes, 17 estão em classe funcional (CF) I e 6 em CF II da NYHA. CONCLUSÃO: O diagnóstico de flail mitral valve ao ecocardiograma transesofágico é acurado, permitindo a definição de sua etiologia e mecanismo. A alta mortalidade à época do diagnóstico, provavelmente, se relaciona à gravidade da doença subjacente. Embora os pacientes não operados estejam evoluindo bem, a baixa CF observada nestes pacientes pode ser atribuída ao curto período de seguimento. PURPOSE: To describe transesophageal echocardiographic findings in patients presenting with flail mitral valve and to obtain their clinical follow-up. METHODS: From January/93 to March/97, 1675 patients were submitted to transesophageal echocardiogram at our institution; 35 of them were diagnosed as having flail mitral valve and their clinical follow-up was obtained. RESULTS: Thirty-five patients with the diagnosis of flail mitral valve were studied. Mean age was 65±15 years (12-87) and 27 (77%) were male. The posterior leaflet was involved in 25 (71%) patients. Ruptured chordae tendineae was present in all but one patient in whom flail mitral valve was due to a very elongated and redundant chordae. The etiology was prolapse and/or mixomatous degeneration in 16 patients, degenerative in 10, ischemic in 5, rheumatic in 4 and endocarditis in 3. Mitral regurgitation was severe in 25 (71%) patients and moderate in 10 (29%). The mean follow-up was 375±395 days (1 to 1380). Nineteen patients were followed clinically and 16 were submitted to surgery (transesophageal echocardiogram findings were confirmed in all 16). Overall mortality was high (34%). Among the survivors, 17 are in NYHA class I and 6 in class II. CONCLUSION: The diagnosis of flail mitral valve by transesophageal echocardiography is accurate, allowing for the definition of its mechanism and etiology, as well as the evaluation of hemodynamic compromise. The observed high mortality at the time of diagnosis may be related to the severity of the disease causing the flail mitral valve. Although non-operated survivors are doing well, the observed low functional class in these patients may be related to the short period of follow-up.